Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
News|Articles|October 22, 2015
FDA Approves Impax’s Generic Version of Intuniv (Guanfacine) Extended-Release Tablets
Author(s)Pharmaceutical Technology Editors
Impax Laboratories announced that FDA has approved its generic version of guanfacine extended-release tablets 1 mg, 2 mg, 3 mg, and 4 mg.
Advertisement
Impax Laboratories announced that FDA has approved its generic version of guanfacine extended-release tablets 1 mg, 2 mg, 3 mg, and 4 mg. The drug is used for the treatment of attention deficit hyperactivity disorder in children and adolescents ages six to 17.
Figures from IMS Health showed that US brand and generic sales of guanfacine extended-release tablets 1 mg, 2 mg, 3 mg, and 4 mg were approximately $689 million for the 12 months ending in August 2015.
Source:
Advertisement
Related to this article
Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What the Olanzapine Depot Approval Means for CMC Teams
2
Q&A: Patient-Centric Drug Development Should Start at Product Definition
3
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
4
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
5